ONC
BeOne Medicines AGHealthcare · $38.6B market cap
Verdict
We can't put a fair value on ONC right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow ONC
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 1, 2026: no open-market purchases, 9 sales worth $13.4M and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Wang Xiaodong
director · 2026-09-08
Sold
$2.2M
Wang Xiaodong
director · 2026-09-08
Sold
$2.3M
Wang Xiaodong
director · 2026-09-08
Sold
$3.7M
Wang Xiaodong
director · 2026-09-08
Sold
$2.6M
Wang Xiaodong
director · 2026-09-08
Sold
$599K
Other filings
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works